Hamilton Thorne Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Kate Torchilin

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Aug 15

Announcing: Hamilton Thorne (CVE:HTL) Stock Soared An Exciting 590% In The Last Five Years

Jan 19

Are Insiders Selling Hamilton Thorne Ltd. (CVE:HTL) Stock?

Jan 06

What Did Hamilton Thorne's (CVE:HTL) CEO Take Home Last Year?

Dec 24

We Think Hamilton Thorne (CVE:HTL) Can Stay On Top Of Its Debt

Dec 12

Is It Time To Consider Buying Hamilton Thorne Ltd. (CVE:HTL)?

Nov 30

A Look At The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)

Nov 17

Here's Why Hamilton Thorne (CVE:HTL) Can Manage Its Debt Responsibly

Aug 24

Is Now An Opportune Moment To Examine Hamilton Thorne Ltd. (CVE:HTL)?

Aug 10

At CA$1.43, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

Aug 10

A Look At The Intrinsic Value Of Hamilton Thorne Ltd. (CVE:HTL)

Jul 27

CEO

Kate Torchilin

less than a year

Permanencia

Ms. Ekaterina Torchilin PhD, MBA, also known as Kate, is President, Chief Executive Officer and Director of Hamilton Thorne Ltd. from January 15, 2024. She serves as Chief Executive Officer of Biocell Cent...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Wolf	Executive Chairman	12.6yrs	US$536.59k	2.14% $ 4.5m
Francesco Fragasso	Chief Financial Officer	1.6yrs	US$151.26k	0.018% $ 38.6k
Brett Fulton	Senior VP & GM	2.9yrs	US$300.60k	sin datos
Ekaterina Torchilin	President	less than a year	sin datos	sin datos
Thomas Kenny	Senior Vice President Global Operations & Sustaining Engineering and Management Rep	no data	US$165.49k	sin datos
Justin Jaundoo	Vice President of Corporate Development	no data	sin datos	sin datos
Kimberly Marolda	Director of HR	no data	sin datos	sin datos
Eric Dorman	President of Embryotech Laboratories Inc	no data	sin datos	sin datos
Fabian Sell	Chief Executive Officer of Gynemed	no data	US$282.51k	sin datos
Dan Ryan	Finance Controller	no data	sin datos	sin datos

0.9yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de HTL no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Wolf	Executive Chairman	12.6yrs	US$536.59k	2.14% $ 4.5m
Ekaterina Torchilin	President	less than a year	sin datos	sin datos
Robert Potter	Lead Independent Director	14.5yrs	US$47.50k	0.32% $ 671.3k
Daniel Thorne	Independent Director	14.5yrs	sin datos	13.25% $ 27.7m
Bruno Maruzzo	Independent Director	17.1yrs	US$37.50k	0.17% $ 355.0k
Karen Firestone	Independent Director	2.3yrs	US$47.50k	0.060% $ 126.4k
David Sable	Independent Director	7.2yrs	sin datos	0.096% $ 200.4k
Marc Robinson	Independent Director	3.3yrs	sin datos	0.031% $ 64.5k
Meg Spencer	Chairman Emeritus	1.8yrs	sin datos	sin datos
Cynthia Hudson	Member of Scientific Advisory Board	3yrs	sin datos	sin datos
Feng Han	Independent Director	3.2yrs	US$47.50k	0.064% $ 133.9k
Thomas Ebner	Member of Scientific Advisory Board	3yrs	sin datos	sin datos

3.2yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: La junta directiva de HTL se considera experimentada (3.2 años de antigüedad promedio).

Hamilton Thorne Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024

Chair, President & CEO exercised options to buy CA$102k worth of stock.

Chair, President & CEO recently sold CA$101k worth of stock

Hamilton Thorne Ltd. Announces Passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer

High number of new directors

Recent updates

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$0.004 loss per share (vs US$0.013 profit in FY 2022)

Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024

Hamilton Thorne Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024

New major risk - Revenue and earnings growth

Hamilton Thorne Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Hamilton Thorne Ltd. (TSX:HTL) agreed to acquire Gynetics Medical Products N.V. for an enterprise value of €18.3 million.

Consensus EPS estimates increase by 80%

New minor risk - Shareholder dilution

Hamilton Thorne Ltd.(TSXV:HTL) dropped from S&P/TSX Venture Composite Index

Consensus EPS estimates fall by 80%

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.002 profit in 2Q 2022)

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Hamilton Thorne Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Consensus EPS estimates fall by 50%

First quarter 2023 earnings released: EPS: US$0.001 (vs US$0.004 in 1Q 2022)

Hamilton Thorne Ltd. to Report Q1, 2023 Results on May 15, 2023

Chair, President & CEO exercised options to buy CA$102k worth of stock.

Chair, President & CEO recently sold CA$101k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued

Consensus EPS estimates increase by 17%

Now 20% undervalued after recent price drop

Hamilton Thorne Ltd. Announces Passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer

Now 21% undervalued after recent price drop

Hamilton Thorne Ltd. (TSXV:HTL) agreed to acquire Microptic, S.L.

Consensus EPS estimates fall by 33%

Hamilton Thorne Ltd. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.001 (vs US$0.002 in 3Q 2021)

High number of new directors

Hamilton Thorne Ltd. to Report Nine Months, 2022 Results on Nov 22, 2022

Consensus EPS estimates fall by 23%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q2, 2022 Results on Aug 23, 2022

Hamilton Thorne Ltd. Announces CFO Changes

Chair, President exercised options to buy CA$86k worth of stock.

Chair, President exercised options to buy CA$886k worth of stock.

Consensus EPS estimates fall by 20%

At CA$1.40, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q1, 2022 Results on May 19, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Hamilton Thorne Ltd., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Chair, President exercised options to buy CA$293k worth of stock.

Hamilton Thorne Ltd. to Report Q4, 2021 Results on Apr 07, 2022

Is Hamilton Thorne (CVE:HTL) Using Too Much Debt?

High number of new directors

President recently bought CA$75k worth of stock

President recently sold CA$635k worth of stock

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Safely

Second quarter 2021 earnings released: EPS US$0.003 (vs US$0.004 loss in 2Q 2020)

Hamilton Thorne Ltd. (TSXV:HTL) acquired IVFTECH ApS and K4 Technology ApS for an enterprise value of approximately DKK 50 million ($8 million).

President exercised options to buy CA$115k worth of stock.

Should You Think About Buying Hamilton Thorne Ltd. (CVE:HTL) Now?

Consensus EPS estimates increase to US$0.028

First quarter 2021 earnings released: EPS US$0.006 (vs US$0.001 in 1Q 2020)

Hamilton Thorne (CVE:HTL) Will Be Hoping To Turn Its Returns On Capital Around

Independent Director recently bought CA$107k worth of stock

Is Hamilton Thorne (CVE:HTL) A Risky Investment?

Full year 2020 earnings released: EPS US$0.007 (vs US$0.006 in FY 2019)

Estimating The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)

When Should You Buy Hamilton Thorne Ltd. (CVE:HTL)?

New 90-day high: CA$1.50

Hamilton Thorne Ltd. Announces Board Changes